Here’s a roundup of the latest coronavirus-related news.
This week marked 500,000 coronavirus-related deaths in the United States. The COVID-19 vaccination effort is well underway in the US, with over 68.27 million administered doses and 6.8% of the population fully vaccinated against the virus as of press time.
This week, an FDA advisory board confirmed the safety and efficacy of Johnson & Johnson’s COVID-19 vaccine candidate, and experts weigh in on how pharmacists can effectively tackle vaccination programs.
Here’s a roundup of the latest coronavirus-related news:
On Friday, a panel of advisors to the FDA voted to recommend Johnson & Johnson's COVID-19 vaccine, named Ad26.COV2.S, for emergency approval.
Pharmacy leaders have leveraged their experience, their role in interdisciplinary teams, and technology to quickly reinvent approaches to manage long-standing issues exacerbated by the pandemic.
On Wednesday, the FDA released results of an analysis for Johnson & Johnson’s COVID-19 vaccine candidate that supports its authorization for emergency use.
In our final interview segment, Lee Rosebush dives into improving vaccine distribution, addressing costs, and maintaining records while vaccinating for COVID-19.
In part 2 of our interview, Kaitlyn Rivard, PharmD, leads an insightful discussion on the practical side of administering COVID-19 vaccines.
Members of the MJH Life Sciences™ COVID-19 Coalition recently weighed in on the latest COVID-19 pandemic news.
Lee Rosebush of BakerHostetler law firm discussed how pharmacies can avoid regulatory and compliance issues amid their COVID-19 vaccination programs.
A safe COVID-19 vaccine that can be administered to most of the pediatric population is a necessity for ending the pandemic, but trials for younger children have not occurred. The president of the American Academy of Pediatrics (AAP) wrote to key COVID-19 officials about the need to change this.